



Supplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2018

January 31, 2019
NITTO DENKO CORPORATION

CONTENTS

	Page
◆ Business Results	1
◆ Segment Information	2
◆ Segment Information By Geographic Area	3
<u>Revenue to customers outside Japan</u>	

(Note) In the amounts of money in this material, fractions below the shown figures are omitted.
Percentages(%) are rounded to the nearest decimal point.

Forward-looking statements such as those relating to earnings forecasts and other projections contained in this material are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

Business Results

(Unit: Billions of yen (): % of change from the same period of previous year)

		Revenue	Operating Income	Net Income
FY2017 Apr.-Dec.	Results	660.7	109.2	80.4
FY2018 Apr.-Dec.	Results	630.1 (-4.6)	84.1 (-23.0)	60.7 (-24.5)

In our "Summary of Consolidated Financial Statements", from the third quarter ended December 31, 2018, "royalty income", which was previously included in "other income" on the consolidated statements of income, is included in "revenue". Figures for the fiscal year 2017, have been restated to reflect this change.

(Unit: Billions of yen (): % of change from the previous year)

		Revenue	Operating Income	Net Income
Forecasts of FY2018	As of Oct 31	830.0	115.0	84.0
	As of Jan 31	820.0 (-1.2)	100.0 (-13.0)	73.0 (-13.1)

(Billions of yen)

		Depreciation expenses	Capital Investment	R&D Expenditures
FY2018 Apr.-Dec.	Results	34.6	52.7	23.3
Forecasts of FY2018		47.5	70.0	33.0

(Yen/1US\$)

Exchange Rate	Q1	107.9	Q2	109.3	Q3	110.5	Q4	108.0
---------------	----	--------------	----	--------------	----	--------------	----	--------------

Topics

◆ **Nitto announces Phase I clinical trial of NBF-006 for the treatment of KRAS driven tumors in advanced cancer patients is allowed to proceed by the FDA**

Nitto announced that the investigational new drug (IND) application for NBF-006, a ribonucleic acid interference (RNAi)-based treatment for KRAS mutant tumors was allowed to proceed by the US Food and Drug Administration (FDA).

NBF-006 is a novel lyophilized lipid nanoparticle (LNP) formulation which delivers encapsulated small interfering ribonucleic acid (siRNA) active pharmaceutical ingredient designed to inhibit the expression of glutathione-S-transferase P (GST-π) to tumors. GST-π is strongly up-regulated in many cancer types, specifically KRAS-mutant lung, colorectal, and pancreatic cancers and a known regulator of oncogenic pathways. NBF-006 demonstrated significant tumor inhibition in KRAS-mutant non-small cell lung cancer animal models.

Nitto BioPharma, Inc. (Headquarters: San Diego, California) is working promptly to initiate the Phase 1 study.

Segment Information

Revenue & Operating Income by Segment

(Yen in millions)

		FY2017 Results			FY2018 Results				Forecasts		
		3Q (Oct.-Dec.)	Apr-Dec	FY2017	2Q (Jul.-Sep.)	3Q (Oct.-Dec.)		Apr.-Dec.		FY2018	
						Y-o-Y(%)	Y-o-Y(%)	Y-o-Y(%)	Y-o-Y(%)		
Industrial Tape	Functional base products	46,511	132,292	173,835	46,247	46,584	100.2	134,628	101.8	181,000	104.1
	Transportation	43,513	124,117	165,045	41,107	42,364	97.4	123,711	99.7	162,000	98.2
	Revenue	90,025	256,409	338,881	87,354	88,948	98.8	258,340	100.8	343,000	101.2
	Operating income	10,008	27,284	34,976	8,143	8,462	84.6	23,309	85.4	31,000	88.6
Optronics	Information fine materials	123,301	340,705	425,247	104,018	117,514	95.3	306,537	90.0	392,000	92.2
	Flexible printed circuits	11,028	31,788	42,039	11,128	10,416	94.5	32,179	101.2	39,900	94.9
	Processing materials	6,290	18,399	24,439	5,817	5,572	88.6	17,020	92.5	23,100	94.5
	Revenue	140,620	390,892	491,726	120,965	133,503	94.9	355,737	91.0	455,000	92.5
	Operating income	34,655	84,831	91,916	18,519	29,969	86.5	61,530	72.5	70,000	76.2
Life Science	Revenue	5,445	20,815	36,183	5,537	6,638	121.9	23,376	112.3	30,000	82.9
	Operating income	-1,099	626	5,929	-1,811	-459	-	2,595	414.2	2,000	33.7
Others	Revenue	6,345	19,171	25,279	6,090	6,876	108.4	19,255	100.4	27,000	106.8
	Operating income	-32	141	-192	-431	-578	-	-1,356	-	-1,000	-
Elimination &Corporate	Revenue	-9,260	-26,552	-34,693	-9,186	-9,473	-	-26,537	-	-35,000	-
	Operating income	-2,511	-3,620	-6,905	403	-4,634	-	-1,954	-	-2,000	-
Total	Revenue	233,175	660,736	857,376	210,760	226,494	97.1	630,172	95.4	820,000	95.6
	Operating income	41,020	109,263	125,722	24,824	32,758	79.9	84,123	77.0	100,000	79.5

* From the fiscal year 2018, we have changed the attribution of a group company internally in "Industrial Tape", and the change has also been reflected in the figures for the fiscal year 2017.

In our "Summary of Consolidated Financial Statements", from the third quarter ended December 31, 2018, "royalty income", which was previously included in "other income" on the consolidated statements of income, is included in "revenue". Figures for the fiscal year 2017, have been restated to reflect this change.

Segment Information by Geographic Area

(Yen in Millions)

		Japan	Americas	Europe	Asia & Oceania	Total	Eliminations & Corporate	Consolidated Total
		Apr.-Dec. FY2017	Revenue to Outside Customers	157,000	54,975	32,726	416,033	660,736
	Inter-segment Revenue or Transfers	302,406	6,850	3,668	25,404	338,329	-338,329	-
	Revenue Total	459,406	61,826	36,395	441,437	999,065	-338,329	660,736
	Operating Income	72,937	5,611	2,859	28,909	110,317	-1,054	109,263

		Japan	Americas	Europe	Asia & Oceania	Total	Eliminations & Corporate	Consolidated Total
		Apr.-Dec. FY2018	Revenue to Outside Customers	155,513	58,353	33,454	382,850	630,172
	Inter-segment Revenue or Transfers	282,979	7,640	3,264	26,848	320,733	-320,733	-
	Revenue Total	438,493	65,994	36,719	409,699	950,906	-320,733	630,172
	Operating Income	57,342	7,096	2,494	18,379	85,312	-1,188	84,123

Note: Major countries or regions excluding Japan are represented as follows:
 Americas : U.S.A., Mexico, Brazil
 Europe : Belgium, France, Germany, Sweden, Turkey
 Asia & Oceania : China, Korea, Taiwan, Singapore, Malaysia, Hong Kong, Thailand

Revenue to Customers Outside Japan

(Yen in Millions)

		Americas	Europe	Asia & Oceania	Others	Total
		Apr.-Dec. FY2017	Revenue to Customers Outside Japan	50,525	34,151	399,765
	Consolidated Revenue	/				660,736
	Ratio to Consolidated Sales	7.6%	5.2%	60.5%	0.1%	73.5%

		Americas	Europe	Asia & Oceania	Others	Total
		Apr.-Dec. FY2018	Revenue to Customers Outside Japan	53,421	36,068	368,072
	Consolidated Revenue	/				630,172
	Ratio to Consolidated Sales	8.5%	5.7%	58.4%	0.1%	72.7%

Note: Major countries or regions excluding Japan are represented as follows:
 Americas : U.S.A., Mexico, Brazil
 Europe : Belgium, France, Germany, Sweden, Turkey
 Asia & Oceania : China, Korea, Taiwan, Singapore, Malaysia, Hong Kong, Thailand
 Others: African countries